MUSIi001-A-2

HLA-I/II-null SFiPSCs

General

Cell Line

hPSCreg name MUSIi001-A-2
Cite as:
MUSIi001-A-2 (RRID:CVCL_D0JX)
Alternative name(s)
HLA-I/II-null SFiPSCs
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
MUSIi001-A
(SFiPSC01)
MUSIi001-A-1
(B2M-KO-SFiPSC5)
Last update 6th September 2024
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Faculty of Medicine Siriraj Hospital (MUSI)
Owner Faculty of Medicine Siriraj Hospital (MUSI)
Distributors
Derivation country Thailand

External Databases

BioSamples SAMEA112466527
Cellosaurus CVCL_D0JX
Wikidata Q123033134

General Information

Publications
* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
Subclone of

Donor Information

General Donor Information

Sex female
Ethnicity Thai

Phenotype and Disease related information (Donor)

Diseases No disease was diagnosed.
Family history N/A
Is the medical history available upon request? N/A
Is clinical information available? N/A

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

Donor Relations

Other cell lines of this donor

External Databases (Donor)

BioSamples SAMEA104627073

Ethics

Also have a look at the ethics information for the parental line MUSIi001-A .
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation

General

The source cell information can be found in the parental cell line MUSIi001-A.

Reprogramming method

Vector type Non-integrating
Vector Sendai virus
Genes
Is reprogramming vector detectable?
No
Methods used
RT-PCR

Vector free reprogramming

Type of used vector free reprogramming factor(s)
None

Other

Selection criteria for clones The iPSC clone that do not express HLA-I/II was selected.
Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 20 %
CO2 Concentration 5 %
Medium Essential 8™
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
NANOG
Yes
SSEA-4
Yes
TRA 1-60
Yes
TRA 1-81
Yes
OCT-4
Yes
Differentiation Potency

Microbiology / Virus Screening

Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46,XX
Karyotyping method: G-Banding

Other Genotyping (Cell Line)

Genetic Modification

Genetic modifications not related to a disease
Gene knock-out
16p13.13
The B2M and CIITA knockout iPSC line provides a model for studying immunological responses of CD4+ and CD8+ T cells toward HLA-null allogeneic cell products. Furthermore, the HLA-null iPSC line can be used as a starting line to develop hypoimmunogenic cell products to prevent T cell recognition for application in allogeneic cell-based therapy.
CRISPR-associated (CRISPR/Cas) System